Challenging the platinum combinations: Docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer

Seminars in Oncology

Volumn 28, Issue 1 SUPPL. 2, 2001, Pages 15-21

  Georgoulias, Vassillis ^a,g   Scagliotti, Giorgio ^a,b,c,d,e,f   Miller, Vincent ^a,b,c,d,e,f   Eckardt, John ^a,b,c,d,e,f   Douillard, Jean Yves ^a,b,c,d,e,f   Manegold, Christian ^a,b,c,d,e,f  

^a University General Hospital of Iraklion   (Greece)

^b UNIVERSITY OF TURIN   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d ST JOHN S MERCY MEDICAL CENTER   (United States)

^e CENTRE RENÉ GAUDUCHEAU   (France)

^f Thoraxklinik   (Germany)

^g UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LACRIMATION; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUROTOXICITY; ONYCHOLYSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0035078758     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.18391     Document Type: Review

References (33)

1. Chemotherapy in NSCLC: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Significantly higher survival with gemcitabine-cisplatin vs cisplatin in advanced non small cell lung cancer (NSCLC): Final results from an international randomized phase III study
3. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study
4. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer
5. Preliminary results. Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer
6. New options in the treatment of non-small cell lung cancer
7. Gemcitabine: Single agent and combination therapy in non-small cell lung cancer
8. Docetaxel and gemcitabine combinations in non-small cell lung cancer
9. Phase I study of docetaxel and gemcitabine combination chemotherapy in chemotherapy naive patients with advanced or metastatic non-small cell lung cancer
10. Phase I study of docetaxel in combination with gemcitabine as first line chemotherapy in patients with metastatic non-small cell lung cancer
11. Phase I and pharmacokinetic study of docetaxel and gemcitabine in patients with non-small cell lung cancer
12. Combination of docetaxel and gemcitabine in the treatment of advanced non-small cell lung cancer
13. Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer (NSCLC): Preliminary results
14. Docetaxel (Taxotere) plus gemcitabine (Gemtro). A new combination in the treatment of patients with advanced non-small cell lung cancer. A preliminary analysis
15. Docetaxel and gemcitabine in metastatic non-small cell lung cancer. A phase II study. Preliminary feasibility report
16. Treatment of advanced non-small cell lung carcinomas with Taxotere, gemcitabine and G-CSF
17. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
18. A phase II study of docetaxel and gemcitabine as second-line treatment in patients with advanced non-small cell lung cancer
19. Single-agent vinorelbine in the treatment on non-small cell lung cancer
20. Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer
21. Phase I trial of docetaxel (DTX) and vinorelbine (VNR) with filgrastim (G-CSF) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
22. Phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy
23. Phase I study of docetaxel in combination with vinorelbine in chemotherapy naive patients with advanced non-small cell lung cancer
24. Phase I trial of weekly docetaxel and vinorelbine in advanced non-small cell lung cancer
25. Docetaxel (Taxotere) in combination with vinorelbine non-small cell lung cancer
26. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer
27. First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine
28. Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine. A preliminary report of an active regimen
29. Phase I/II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC)
30. Gemcitabine plus paclitaxel in NSCLC. Preliminary data of a phase I/II study
31. Phase I study of paclitaxel (P) over 1 hr infusion in combination with vinorelbine (V) in advanced non-small cell lung cancer (NSCLC)
32. Pilot study of vinorelbine and paclitaxel in patients with refractory non-small cell lung cancer
33. The Norton-Simon hypothesis revisited